Intravenous versus oral iron supplementation in peritoneal dialysis patients

Peritoneal Dialysis International

Volumn 27, Issue SUPPL. 2, 2007, Pages

  Johnson, David W ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Darbepoetin; Erythropoietin; Ferritin; Hemoglobin; Iron economics; Prospective studies

Indexed keywords

ERYTHROPOIETIN; FERRIC HYDROXIDE SUCROSE; FERROUS FUMARATE; FERROUS GLUCONATE; FERROUS SULFATE; FERUMOXYTOL; HEMOGLOBIN; HISTAMINE H2 RECEPTOR ANTAGONIST; IRON; IRON DEXTRAN; IRON POLYMALTOSE; IRON SACCHARATE; PHOSPHATE BINDING AGENT; PLACEBO; POLYPEPTIDE;

ABDOMINAL PAIN; ANAPHYLAXIS; ARTHRALGIA; BACKACHE; CARDIOVASCULAR DISEASE; CHILL; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS PATIENT; HUMAN; HYPOTENSION; INFECTION; INJECTION SITE PAIN; IRON BALANCE; IRON STORAGE; MAXIMUM PERMISSIBLE DOSE; MYALGIA; NAUSEA; PARESTHESIA; PATIENT MONITORING; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; VOMITING;

ADMINISTRATION, ORAL; CLINICAL TRIALS AS TOPIC; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FERRIC COMPOUNDS; FERRITINS; FERROUS COMPOUNDS; HEMOGLOBINS; HUMANS; INFUSIONS, INTRAVENOUS; IRON; PERITONEAL DIALYSIS; TRANSFERRIN;

EID: 35748951336     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (51)

1. Valderrabano F. Erythropoietin in chronic renal failure. Kidney Int 1996; 50:1373-91.
2. Benz RL, Pressman MR, Hovick ET, Peterson DD. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (the SLEEPO study). Am J Kidney Dis 1999; 34:1089-95.
3. Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int 1999; 55(Suppl 69):S61-6.
4. Macdougall IC. Optimizing erythropoietin therapy. Curr Opin Hematol 1999; 6:121-6.
5. Jacobs C, Frei D, Perkins AC. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Nephrol Dial Transplant 2005; 20(Suppl 3):iii3-24.
6. Allegra V, Mengozzi G, Vasile A. Iron deficiency in maintenance hemodialysis patients: assessment of diagnosis criteria and of three different iron treatments. Nephron 1991; 57:175-82.
7. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50:1694-9.
8. Schaefer RM, Schaefer L. Management of iron substitution during r-HuEPO therapy in chronic renal failure patients. Erythropoiesis 1992; 3:71-5.
9. Drueke TB, Bárány P, Cazzola M, Eschbach JW, Grutzmacher P, Kaltwasser JP, et al. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients. Clin Nephrol 1997; 48:1-8.
10. Muirhead N, Bargman J, Burgess E, Jindal KK, Levin A, Nolin L, et al. Evidence-based recommendations for the clinical use of recombinant human erythropoietin. Am J Kidney Dis 1995; 26(Suppl 1):S1-24.
11. Fishbane S, Maesaka JK. Iron management in end-stage renal disease. Am J Kidney Dis 1997; 29:319-33.
12. Horl WH, Cavill I, Macdougall IC, Schaefer RM, Sunder Plassmann G. How to diagnose and correct iron deficiency during r-huEPO therapy - a consensus report. Nephrol Dial Transplant 1996; 11:246-50.
13. Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19(Suppl 2):ii1-47.
14. IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 2001; 37(Suppl 1):S182-238.
15. Pollock CA, Saltissi D, Roger S, Healy H, Barratt L, Elder G, et al. Biochemical and haematological targets. In: Knight J, Chu R, Smith J, Gerard J, eds. The CARI Guidelines. Sydney: Excerpta Medica Communications; 2000: 19-26.
16. Barrett BJ, Fenton SS, Ferguson B, Halligan P, Langlois S, Mccready WG, et al. Clinical practice guidelines for the management of anemia coexistent with chronic renal failure. J Am Soc Nephrol 1999; 10(Suppl 13):S292-6.
17. Aronoff GR. Safety of intravenous iron in clinical practice: implications for anemia management protocols. J Am Soc Nephrol 2004; 15(Suppl 2):S99-106.
18. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 2004; 19:1571-5.
19. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16:3070-80.
20. St Peter WL, Obrador GT, Roberts TL, Collins AJ. Trends in intravenous iron use among dialysis patients in the United States (1994-2002). Am J Kidney Dis 2005; 46:650-60.
21. Bárány P, Clyne N, Hylander B, Johansson AC, Simonsen O, Larsson R, et al. Subcutaneous epoetin beta in renal anemia: an open multicenter dose titration study of patients on continuous peritoneal dialysis. Perit Dial Int 1995; 15:54-60.
22. Nissenson AR, Korbet S, Faber M, Burkart J, Gentile D, Hamburger R, et al. Multicenter trial of erythropoietin in patients on peritoneal dialysis. J Am Soc Nephrol 1995; 5:1517-29.
23. Nyvad O, Danielsen H, Madsen S. Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients. Lancet 1994; 344:1305-6.
24. Macdougall IC, Davies ME, Hutton RD, Cavill I, Lewis NP, Coles GA, et al. The treatment of renal anaemia in CAPD patients with recombinant human erythropoietin. Nephrol Dial Transplant 1990; 5:950-5.
25. Domoto DT, Martin KJ. Failure of CAPD patients to respond to an oral iron absorption test. Adv Perit Dial 1992; 8:102-4.
26. Bastani B, Islam S, Boroujerdi N. Iron absorption after single pharmacological oral iron loading test in patients on chronic peritoneal dialysis and in healthy volunteers. Perit Dial Int 2000; 20:662-6.
27. Richardson D, Bartlett C, Jolly H, Will EJ. Intravenous iron for CAPD populations: proactive or reactive strategies? Nephrol Dial Transplant 2001; 16:115-19.
28. Vychytil A, Haag-Weber M. Iron status and iron supplementation in peritoneal dialysis patients. Kidney Int 1999; 55(Suppl 69):S71-8.
29. Ahsan N. Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: a single center comparative study. J Am Soc Nephrol 1998; 9:664-8.
30. Ahsan N. Infusion of total dose iron versus oral iron supptementation in ambulatory peritoneal dialysis patients: a prospective, crossover trial. Adv Perit Dial 2000; 16:80-4.
31. Silverberg DS, Blum M, Peer G, Kaplan E, Iaina A. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 1996; 72:413-17.
32. Johnson DW, Herzig KA, Gissane R, Campbell SB, Hawley CM, Isbel NM. A prospective cross-over trial comparing intermittent intravenous and continuous oral iron supplementation in peritoneal dialysis patients. Nephrol Dial Transplant 2001; 16:1879-84.
33. Fishbane S, Goreja MAJ, Maesaka JK. Reduced nPCR in patients with gastrointestinal side effects due to ferrous sulfate [Abstract]. J Am Soc Nephrol 1998; 9:248A.
34. Macdougall IC, Chandler G, Armstrong A, Breen C, Harchowal J, Cavill J. Characterisation of iron availability from 3 different iron preparations in dialysis patients [Abstract]. J Am Soc Nephrol 1997; 8:221.
35. Chandler GH. Intravenous iron hydroxy saccharate: establishing the optimum dose [Abstract]. J Am Soc Nephrol 2001; 8:217.
36. Fishbane S, Ungureanu VD, Maesaka JK, Kaupke CJ, Lim V, Wish J. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996; 28:529-34.
37. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 1999; 33:464-70.
38. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981; 1:1293-4.
39. Patruta SI, Edlinger R, Sunder-Plassmann G, Horl WH. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 1998; 9:655-63.
40. Hoen B, Kessler M, Hestin D, Mayeux D. Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicentre prospective survey. Nephrol Dial Transplant 1995; 10:377-81.
41. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9:869-76.
42. Prakash S, Walele A, Dimkovic N, Bargman J, Vas S, Oreopoulos D. Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients. Perit Dial Int 2001; 21:290-5.
43. Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002; 106:2212-17.
44. Feldman HI, Santanna J, Guo W, Furst H, Franklin E, Joffe M, et al. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 2002; 13:734-44.
45. Feldman HI, Joffe M, Robinson B, Knauss J, Cizman B, Guo W, et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004; 15: 1623-32.
46. Grasbeck R, Kouvonen I, Lundberg M, Tenhunen R. An intestinal receptor for heme. Scand J Haematol 1979; 23:5-9.
47. Hallberg L, Ryttinger L, Solvell L. Side-effects of oral iron therapy. A double-blind study of different iron compounds in tablet form. Acta Med Scand Suppl 1966; 459:3-10.
48. Seligman PA, Moore GM, Schleicher RB. Clinical studies of HIP: an oral heme-iron product. Nutr Res 2000; 20: 1279-86.
49. Hallberg L, Hulten L, Gramatkovski E. Iron absorption from the whole diet in men: how effective is the regulation of iron absorption? Am J Clin Nutr 1997; 66:347-56.
50. Nissenson AR, Berns JS, Sakiewicz P, Ghaddar S, Moore GM, Schteicher RB, et al. Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients. Am J Kidney Dis 2003; 42:325-30.
51. Spinowitz BS, Schwenk MH, Jacobs PM, Bolton WK, Kaplan MR, Charytan C, et al. The safety and efficacy of ferumoxytot therapy in anemic chronic kidney disease patients. Kidney Int 2005; 68:1801-7.